Michael Green, PhD

Thank you to @AACR, @AACR_CEO, @BCD_AACR and @icmlugano for supporting #aacrlymph24, and for all that attended. It was a great opportunity for interaction and idea exchange to drive lymphoma research forward. Looking forward to the next meeting in 2 years. Pencil it in! #lmsm

Save-the-date: AACR/ICML Advances In Malignant Lymphoma, June 24-27, 2026, Philadelphia. Featuring interactive sessions focused on the cutting edge of basic and translational research in Lymphoma. @AACR @icmlugano #lmsm

Lymphoma Microenvironment Archetype Profiles (LymphoMAPs). Just presented by @dgermain21 at #18icml @icmlugano, now available online in Cancer Cell. #lmsm @washumedicine @MDAndersonNews. cell.com/cancer-cell/fu…

Thrilled to see @dgermain21 present our work as a plenary at #18ICML, with excellent discussion from Steve Ansell. The paper will be online tonight, with a summary to follow.

For those of you who have had a hard time with papers, this was a doozie. Several editorial desk rejections, all for different reasons, and then an extensive 41-page rebuttal required for revision at Blood. All told, ~2 years from first submission to acceptance. Just keep at it!!

Why is it that journals do not have the same data sharing standards for pharma as they do for academia? There is always a vague statement that you can email the company to request the data. But, after you've told the company all your ideas, the answer is invariably no.

#ESHLYMPHOID2025 REGISTRATION AND ABSTRACT SUBMISSION ARE OPEN ➡ bit.ly/4cTSoce Oct 2-4, 2025 in Estoril, Portugal 🇵🇹 8th Translational Research Conference LYMPHOID MALIGNANCIES Chairs: @HallekMichael, Georg Lenz, @SehnLaurie, @LouisStaudt, Catherine Wu #ESHCONFERENCES

Voting is open for the @ASCO elections. Please consider casting a vote for Dr. Jason Westin @Lymphoma_Doc for the Board of Directors. Jason is a thoughtful and visionary leader with a proven track record of contribution to ASCO. #lmsm @MDAndersonNews

Transcriptional/epigenetic chemical inducers of proximity (TCIPs) are an innovative new class of therapeutics that are set to impact lymphoma and other malignancies. Here @RomanSarott, @saigourisankar describe a CDK9 "catch and release" MOA for a new TCIP. science.org/doi/10.1126/sc…

Ready for day 2 of the @AACR Advances in Malignant Lymphoma meeting. Kicking off the morning with abstract presentations, then into sessions on premilgnancy and clonal precursors. Looking forward to it! #aacrlymph24 @BCD_AACR #lmsm

Opening the @aacr Advances in Malignant Lymphoma meeting tonight with a fabulous keynote from Dr. Tak Mak, University of Toronto. Tet2+Idh2 mutations in AITL makes T-cells "party hard in the germinal center". #AACRlymph24

The abstract deadline is this Friday for the AACR/ICML International Meeting on Advances in Malignant Lymphoma. Come and join us at this one-of-a-kind Lymphoma-focused meeting. #lmsm

The abstract deadline is approaching. This is set to be a great conference with an excellent speaker line-up and formatted to support debate and interaction. Come and join us in Philly. #lmsm @LabMelnick @ChrisRFlowersMD @frbertoni

Submit an abstract by April 1 for the Fourth AACR International Meeting on Advances in Malignant Lymphoma (June 19-22, Philadelphia), chaired by Michael R. Green and organized in association with @BCD_AACR. Learn more: bit.ly/49fzmK6 #AACRlymph24 @GreenLymphoLab

This is team science! 🤝 A big shoutout to @LeeGrimesLab, @Krauselab_Yale, @PittTweet (Singh lab) & @CraigTJordanLab. Funded mostly by an RC2 grant from @NIH, @NIDDKgov, @ShilpaH75. Kudos to @BioLegend, @CytekBio & Curiox Biosystems for their support with prototype products! 3/3